Is Bristol-Myers Squibb Company a good dividend stock?

Bristol-Myers Squibb Company (BMY) is a dividend-paying stock with a current dividend yield of 4.36%. Review its dividend history, payout consistency and growth to judge whether it fits your income strategy.

What is BMY's dividend yield?

The dividend yield for BMY stock is currently 4.36%.

How much does BMY pay in dividends per year?

Bristol-Myers Squibb Company pays an annual dividend of $2.5100 per share over the trailing twelve months.

How often does BMY pay dividends?

BMY stock pays dividends quarterly.

Is BMY's dividend growing?

Bristol-Myers Squibb Company's 3-year dividend CAGR is 4.04%.

BMY Stock Price, Chart, Stats & News

Bristol-Myers Squibb Company

Save

Overview Dividend safety Dividends Fundamentals

Bristol-Myers Squibb Company (BMY) is a dividend-paying stock with a current dividend yield of 4.36% as of Jul 10, 2026. It pays $2.51 per share over the trailing twelve months and distributes quarterly. Its dividend has grown at a 5.87% 5-year compound annual rate.

117.58B

Market cap

9.71x

Current P/E

9.12x

Forward P/E

4.36%

Dividend yield

$2.51

BMY dividend

Dividend safety

Strong

Dividend coverage looks healthy — BMY pays out about 42% of earnings.

See the safety analysis

BMY chart

Loading chart...

Fundamentals

Gross margin	67.65%
Operating margin	26.34%
Pretax margin	19.36%
Net margin	14.63%
Effective tax rate	24.36%
ROA	7.83%
ROE	39.27%
D/E	2.55x
Interest coverage ratio	8.41x

All financials

BMY valuation

P/E	9.71x
P/S	2.47x
P/B	6.47x
P/CF	8.44x
P/FCF	9.28x
P/OCF	8.44x
PEG	1.03x
EV multiple	5.66x

About

Health care

Sector

Drug Manufacturers - General

Industry

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism.